The potential for CETP inhibition to reduce cardiovascular disease risk

References

• American Heart Association. Heart disease and stroke statistics – 2005 update. Dallas, TX: American Heart Association, 2005
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Executive Summary. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24: 1601–10
   Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9
   Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–8
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   Google Scholar
• The Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274–5
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14
   PubMed Web of Science ®Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835–8
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11–20
   Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108–13
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–8
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–45
   Google Scholar
• The coronary drug project. JAMA 1972;221:918
   Web of Science ®Google Scholar
• Dunbar RL, Rader DJ. HDL cholesterol as a target of therapy. Nat Lipid Assoc Lipid Spin 2004;2:5
   Google Scholar
• Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234–8
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• O’Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. Circulation 2001;104:1978–83
   Google Scholar
• Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004;109\(Suppl 1):III8–14
   Google Scholar
• Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105:1399–402
   PubMed Web of Science ®Google Scholar
• Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7:853–7
   PubMed Web of Science ®Google Scholar
• Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000;275:11278–83
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109\(Suppl 1):III27–32
   Google Scholar
• Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495–508
   PubMed Web of Science ®Google Scholar
• Watson AD, Navab M, Hama SY, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95:774–82
   PubMed Web of Science ®Google Scholar
• Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000;20:1716–23
   Google Scholar
• Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002;13:285–8
   Google Scholar
• Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108–12
   PubMed Web of Science ®Google Scholar
• Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039–46
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758–67
   Google Scholar
• Sugatani J, Miwa M, Komiyama Y, et al. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 1996;13:73–88
   PubMedGoogle Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–43
   PubMed Web of Science ®Google Scholar
• Navab M, Ananthramaiah GM, Reddy ST, et al. The double jeopardy of HDL. Ann Med 2005;37:173–8
   PubMed Web of Science ®Google Scholar
• Epand RM, Stafford A, Leon B, et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994;14:1775–83
   PubMed Web of Science ®Google Scholar
• Fleisher LN, Tall AR, Witte LD, et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982;257:6653–5
   PubMed Web of Science ®Google Scholar
• Viswambharan H, Ming XF, Zhu S, et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 2004;94:918–25
   PubMed Web of Science ®Google Scholar
• Hajduk SL, Moore DR, Vasudevacharya J, et al. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J Biol Chem 1989;264:5210–7
   PubMed Web of Science ®Google Scholar
• Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979;64:1516–24
   Google Scholar
• Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004;101:9774–9
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kennedy MA, Baldan A, et al. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J Biol Chem 2004;279:45980–9
   PubMed Web of Science ®Google Scholar
• Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000;101:2411–7
   PubMed Web of Science ®Google Scholar
• Zhang W, Yancey PG, Su YR, et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2003;108:2258–63
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23: 160–7
   PubMed Web of Science ®Google Scholar
• Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542–56
   PubMed Web of Science ®Google Scholar
• Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339–49
   PubMedGoogle Scholar
• Newnham HH, Barter PJ. Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma. Biochim Biophys Acta 1990;1044:57–64
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Klerkx AH, Stroes ES, et al. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45: 1967–74
   PubMed Web of Science ®Google Scholar
• Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989;342:448–51
   PubMed Web of Science ®Google Scholar
• Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese–American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917–23
   PubMed Web of Science ®Google Scholar
• Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004;45:948–53
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323–9
   PubMed Web of Science ®Google Scholar
• Ikewaki K, Mabuchi H, Teramoto T, et al. Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects. Metabolism 2003;52:1564–70
   PubMed Web of Science ®Google Scholar
• Corella D, Saiz C, Guillen M, et al. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis 2000;152:367–76
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2003;24:1833–42
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86–93
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003;44:1080–93
   PubMed Web of Science ®Google Scholar
• Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290:2030–40
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004;173:261–7
   PubMed Web of Science ®Google Scholar
• Klerkx AH, de Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004;34:21–8
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition) – Norfolk population study. Circulation 2004;110:1418–23
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003;169:113–20
   PubMed Web of Science ®Google Scholar
• Komori T. CETi-1. AVANT. Curr Opin Investig Drugs 2004;5:334–8
   PubMedGoogle Scholar
• Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203–7
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159–65
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JJT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085–8
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Hovingh GK, El Harchaoui K, et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 2005;25:e133–4
   PubMed Web of Science ®Google Scholar
• Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24:490–7
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505–15
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005;25:1057–64
   PubMed Web of Science ®Google Scholar
• Lloyd DB, Lira ME, Wood LS, et al. Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. J Biol Chem 2005;280:14918–22
   PubMed Web of Science ®Google Scholar
• Davidson M, McKenney J, Revkin JH. Efficacy and safety of a novel CETP inhibitor torcetrapib administered with and without atorvastatin in subjects with a low level of HDL-C. Presented at: 54th Annual Scientific Session of the American College of Cardiology; 7 March 2005; Orlando, FL
   Google Scholar
• Thuren T, Longcore A, Powell C, et al. Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well-tolerated: results from a Phase 2, dose-ranging clinical trial. Presented at: American Heart Association Scientific Sessions 2005; 13–16 November 2005; Dallas, TX
   Google Scholar
• Thuren T, Longcore A, Powell C, et al. Effects of torcetrapib and/or atorvastatin on HDL and LDL particle type, composition, and size: results from a phase 2 trial. Presented at: American College of Cardiology Scientific Sessions 2006; 11–14 March 2006; Atlanta, GA
   Google Scholar
• Revkin J, Shear C. Enhanced LDL-C lowering effect of torcetrapib when administered with atorvastatin to subjects with high baseline triglyceride levels. Presented at: XIV International Symposium on Atherosclerosis; 18–22 June 2006; Rome, Italy
   Google Scholar
• Revkin J, Durham K, Shear C, et al. Inhibition of CETP by torcetrapib raises HDL-C and lowers LDL-C independent of gender or baseline HDL-C levels. Presented at: XIV International Symposium on Atherosclerosis; 18–22 June 2006; Rome, Italy
   Google Scholar
• Bamberger M, Moya M, Durham K, et al. The capacity of HDL to stimulate cholesterol efflux is maintained in subjects with and without low HDL-C treated with torcetrapib. Presented at: XIV International Symposium on Atherosclerosis; 18–22 June 2006; Rome, Italy
   Google Scholar
• Morehouse LA, Sugarman ED, Bourassa PA, et al. HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. Presented at: International Symposium on Drugs Affecting Lipid Metabolism; 24–27 October 2004; Venice, Italy
   Google Scholar
• Gibbs M, Riggs M, Terra S, et al. Lipid effects of torcetrapib with and without atorvastatin are optimized by morning dosing: results from pharmacokinetic/pharmacodynamic analyses. Presented at: American College of Cardiology Scientific Sessions 2006; 11–14 March 2006; Atlanta, GA
   Google Scholar
• Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 2003;327: 788
   Google Scholar
• Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991;11:816–26
   PubMed Web of Science ®Google Scholar
• Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing. Atherosclerosis 1990;85:219–27
   Google Scholar
• Cilla DD Jr, Gibson DM, Whitfield LR, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604–9
   PubMed Web of Science ®Google Scholar
• McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B–32
   Google Scholar
• Kiortsis DN, Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445–51
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar